Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 13  •  04:00PM ET
24.33
Dollar change
+0.73
Percentage change
3.09
%
IndexRUT P/E14.20 EPS (ttm)1.71 Insider Own10.21% Shs Outstand123.26M Perf Week-0.45%
Market Cap2.99B Forward P/E13.87 EPS next Y1.75 Insider Trans-2.20% Shs Float110.37M Perf Month5.01%
Enterprise Value2.30B PEG1.14 EPS next Q0.34 Inst Own80.12% Short Float8.01% Perf Quarter6.80%
Income217.56M P/S5.17 EPS this Y23.21% Inst Trans1.74% Short Ratio7.11 Perf Half Y21.23%
Sales578.20M P/B3.26 EPS next Y8.67% ROA23.86% Short Interest8.84M Perf YTD4.24%
Book/sh7.47 P/C4.33 EPS next 5Y12.19% ROE27.52% 52W High26.58 -8.47% Perf Year4.60%
Cash/sh5.61 P/FCF12.75 EPS past 3/5Y52.99% 34.27% ROIC23.58% 52W Low19.05 27.72% Perf 3Y56.56%
Dividend Est.- EV/EBITDA7.77 Sales past 3/5Y51.71% 36.89% Gross Margin79.21% Volatility3.55% 3.46% Perf 5Y479.29%
Dividend TTM- EV/Sales3.98 EPS Y/Y TTM44.42% Oper. Margin44.76% ATR (14)0.82 Perf 10Y1282.39%
Dividend Ex-Date- Quick Ratio6.40 Sales Y/Y TTM25.56% Profit Margin37.63% RSI (14)53.32 Recom1.14
Dividend Gr. 3/5Y- - Current Ratio6.62 EPS Q/Q18.69% SMA200.62% Beta0.74 Target Price34.57
Payout0.00% Debt/Eq0.00 Sales Q/Q15.31% SMA502.71% Rel Volume0.93 Prev Close23.60
Employees181 LT Debt/Eq0.00 EarningsFeb 25 AMC SMA2009.12% Avg Volume1.24M Price24.33
IPONov 08, 2006 Option/ShortYes / Yes EPS/Sales Surpr.26.51% 8.46% Trades Volume1,156,680 Change3.09%
Date Action Analyst Rating Change Price Target Change
Feb-04-25Initiated Robert W. Baird Outperform $28
Nov-18-24Initiated Stephens Overweight $35
Mar-14-24Initiated Citigroup Buy $27
Mar-07-24Initiated BofA Securities Buy $23
Dec-21-23Initiated Oppenheimer Outperform $30
Aug-24-22Downgrade ROTH Capital Buy → Neutral $10 → $15.50
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-07-18Resumed Piper Jaffray Overweight
Oct-05-16Upgrade Piper Jaffray Neutral → Overweight
Apr-26-16Downgrade Piper Jaffray Overweight → Neutral $6 → $1
Feb-12-26 08:45AM
Feb-11-26 08:03AM
Feb-03-26 09:40AM
Jan-28-26 09:50AM
Jan-24-26 02:20PM
05:18PM Loading…
Jan-19-26 05:18PM
Jan-16-26 12:13PM
Jan-15-26 09:40AM
Jan-09-26 11:40AM
Jan-08-26 09:40AM
08:03AM
Jan-05-26 08:03AM
Dec-30-25 09:40AM
Dec-23-25 09:50AM
Dec-17-25 11:40AM
09:55AM Loading…
09:55AM
09:40AM
09:40AM
Dec-16-25 08:30AM
Dec-15-25 02:59PM
08:03AM
Dec-10-25 10:33AM
Dec-09-25 09:40AM
Dec-05-25 11:30AM
Dec-04-25 09:35AM
09:15AM
Dec-03-25 04:00PM
Dec-02-25 09:50AM
Dec-01-25 11:40AM
09:55AM
09:40AM Loading…
09:40AM
09:40AM
Nov-25-25 08:30AM
Nov-24-25 08:03AM
Nov-19-25 09:41AM
08:03AM
Nov-18-25 08:03AM
Nov-13-25 11:40AM
09:55AM
09:50AM
09:40AM
09:40AM
Nov-06-25 10:43AM
Nov-05-25 06:00PM
05:45PM
04:50PM
04:06PM
Nov-04-25 04:03PM
07:46AM
Nov-03-25 08:03AM
Oct-30-25 10:00AM
Oct-29-25 10:00AM
Oct-24-25 09:45AM
Oct-22-25 08:03AM
Oct-17-25 09:40AM
Oct-10-25 09:50AM
Oct-09-25 08:03AM
Oct-08-25 09:45AM
12:57AM
Oct-01-25 09:40AM
08:03AM
Sep-22-25 09:45AM
Sep-15-25 09:40AM
Sep-02-25 04:26PM
Aug-29-25 09:40AM
04:54AM
Aug-28-25 08:03AM
Aug-26-25 07:12PM
11:16AM
Aug-25-25 08:03AM
Aug-15-25 09:45AM
Aug-13-25 09:40AM
Aug-07-25 10:08AM
09:15AM
Aug-06-25 07:00PM
06:40PM
05:37PM
04:13PM
08:03AM
Aug-05-25 09:40AM
09:32AM
Aug-04-25 08:03AM
Aug-01-25 09:40AM
Jul-30-25 10:00AM
Jul-28-25 11:40AM
Jul-24-25 09:45AM
04:04AM
Jul-23-25 10:35AM
Jul-22-25 08:07AM
08:03AM
Jul-21-25 09:40AM
Jul-17-25 09:11AM
Jul-16-25 09:40AM
09:01AM
Jul-09-25 11:40AM
Jul-07-25 09:45AM
Jul-04-25 09:40AM
Jun-30-25 09:40AM
Jun-26-25 09:35AM
Jun-23-25 11:40AM
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Harper MollyDirectorDec 12 '25Option Exercise5.7820,000115,60029,106Dec 16 05:00 PM
Harper MollyDirectorDec 12 '25Sale23.2526,746621,9202,360Dec 16 05:00 PM
Harper MollyDirectorDec 12 '25Proposed Sale23.2526,746621,929Dec 12 04:25 PM
Del Carmen JeffreyChief Commercial OfficerNov 26 '25Option Exercise4.2110,98346,23814,945Nov 28 05:00 PM
Del Carmen JeffreyChief Commercial OfficerNov 26 '25Sale23.3310,983256,2443,962Nov 28 05:00 PM
Del Carmen JeffreyOfficerNov 26 '25Proposed Sale23.3310,983256,247Nov 26 01:54 PM
Elsbernd BrianOfficerNov 12 '25Proposed Sale22.7040,000907,934Nov 12 01:23 PM
Elsbernd BrianChief Compliance/Legal OfficerSep 08 '25Option Exercise2.24112,475251,944301,039Sep 10 05:00 PM
Elsbernd BrianChief Compliance/Legal OfficerSep 08 '25Sale20.3030,000609,000271,039Sep 10 05:00 PM
Elsbernd BrianOfficerSep 08 '25Proposed Sale20.3030,000609,035Sep 08 02:52 PM
Elsbernd BrianChief Compliance/Legal OfficerSep 04 '25Option Exercise2.2430,00067,200218,564Sep 05 05:00 PM
Elsbernd BrianChief Compliance/Legal OfficerSep 03 '25Option Exercise2.2420,00044,800208,564Sep 05 05:00 PM
Elsbernd BrianChief Compliance/Legal OfficerSep 04 '25Sale19.5230,000585,600188,564Sep 05 05:00 PM
Elsbernd BrianChief Compliance/Legal OfficerSep 03 '25Sale20.0820,000401,600188,564Sep 05 05:00 PM
Elsbernd BrianOfficerSep 04 '25Proposed Sale19.5230,000585,641Sep 04 11:28 AM
Elsbernd BrianOfficerSep 03 '25Proposed Sale20.0820,000401,514Sep 03 12:19 PM
Tierney David SDirectorAug 27 '25Option Exercise2.2450,000112,000405,620Aug 28 05:00 PM
Tierney David SDirectorAug 27 '25Sale20.2026,000525,200379,620Aug 28 05:00 PM
Miller SteveChief Op. & Scientific OfficerAug 26 '25Option Exercise2.24115,000257,6001,064,663Aug 28 05:00 PM
Miller SteveChief Op. & Scientific OfficerAug 27 '25Option Exercise2.24110,000246,4001,059,663Aug 28 05:00 PM
Miller SteveChief Op. & Scientific OfficerAug 26 '25Sale20.28115,0002,332,200949,663Aug 28 05:00 PM
Daly Richard JPresident and CEOAug 26 '25Option Exercise2.2450,000112,000249,764Aug 28 05:00 PM
Daly Richard JPresident and CEOAug 26 '25Sale20.6222,970473,641226,794Aug 28 05:00 PM
Tierney David SDirectorAug 27 '25Proposed Sale20.2026,000525,088Aug 27 04:14 PM
Miller SteveOfficerAug 26 '25Proposed Sale20.28115,0002,332,370Aug 26 01:07 PM
Daly Richard JOfficerAug 26 '25Proposed Sale20.6222,970473,641Aug 26 10:46 AM
Sundaram PreethiChief Strategy OfficerJun 10 '25Sale26.412,32461,37742,681Jun 12 05:00 PM
Sundaram PreethiChief Strategy OfficerJun 11 '25Sale26.421,60042,27241,081Jun 12 05:00 PM
Sundaram PreethiOfficerJun 11 '25Proposed Sale26.421,60042,268Jun 11 04:21 PM
MCENANY PATRICK JChairman of Board of DirectorsJun 09 '25Sale26.11171,7484,484,3404,281,702Jun 10 05:00 PM
MCENANY PATRICK JChairman of Board of DirectorsJun 06 '25Sale25.9528,252732,9984,453,450Jun 10 05:00 PM
Sundaram PreethiOfficerJun 10 '25Proposed Sale26.412,32461,383Jun 10 04:13 PM
MCENANY PATRICK JDirectorJun 06 '25Proposed Sale25.88200,0005,176,000Jun 06 03:42 PM
O'Keeffe Charles BFormer DirectorJun 02 '25Proposed Sale25.008,222205,550Jun 02 02:44 PM
O'Keeffe Charles BFormer DirectorMay 30 '25Proposed Sale25.0141,7781,044,973May 30 04:32 PM
Daly Richard JOfficerMay 30 '25Proposed Sale24.8670,0001,740,172May 30 04:04 PM
INGENITO GARYChief Med. & Reg. OfficerMay 13 '25Option Exercise3.42200,000684,000268,873May 15 05:00 PM
INGENITO GARYChief Med. & Reg. OfficerMay 14 '25Option Exercise4.6444,000204,160112,873May 15 05:00 PM
INGENITO GARYChief Med. & Reg. OfficerMay 13 '25Sale23.68200,0004,736,00068,873May 15 05:00 PM
INGENITO GARYChief Med. & Reg. OfficerMay 14 '25Sale23.6344,0001,039,72068,873May 15 05:00 PM
INGENITO GARYOfficerMay 14 '25Proposed Sale23.6344,0001,039,720May 14 10:45 AM
INGENITO GARYOfficerMay 13 '25Proposed Sale23.98200,0004,796,000May 13 11:14 AM
INGENITO GARYChief Med. & Reg. OfficerMar 06 '25Option Exercise2.24180,096403,415248,969Mar 07 05:00 PM
INGENITO GARYChief Med. & Reg. OfficerMar 05 '25Option Exercise2.2444,904100,585113,777Mar 07 05:00 PM
INGENITO GARYChief Med. & Reg. OfficerMar 06 '25Sale21.67180,0963,902,68068,873Mar 07 05:00 PM
INGENITO GARYChief Med. & Reg. OfficerMar 05 '25Sale22.0944,904991,92968,873Mar 07 05:00 PM
INGENITO GARYOfficerMar 06 '25Proposed Sale21.67180,0963,903,251Mar 06 04:17 PM
Elsbernd BrianChief Compliance/Legal OfficerMar 03 '25Option Exercise2.2462,525140,056241,819Mar 05 05:00 PM
Elsbernd BrianChief Compliance/Legal OfficerMar 03 '25Sale22.9862,9751,446,933188,564Mar 05 05:00 PM
Del Carmen JeffreyChief Commercial OfficerMar 03 '25Sale22.8930,423696,3820Mar 05 05:00 PM
INGENITO GARYOfficerMar 05 '25Proposed Sale22.0944,904991,911Mar 05 04:09 PM
Elsbernd BrianOfficerMar 03 '25Proposed Sale22.9762,5251,436,446Mar 03 04:21 PM
Del Carmen JeffreyOfficerMar 03 '25Proposed Sale22.8930,423696,382Mar 03 10:21 AM
Last Close
Feb 13  •  04:00PM ET
8.50
Dollar change
+0.10
Percentage change
1.19
%
ZVRA Zevra Therapeutics Inc daily Stock Chart
IndexRUT P/E13.47 EPS (ttm)0.63 Insider Own1.33% Shs Outstand56.22M Perf Week-1.16%
Market Cap478.53M Forward P/E15.32 EPS next Y0.56 Insider Trans-14.23% Shs Float55.55M Perf Month-7.31%
Enterprise Value341.74M PEG- EPS next Q0.05 Inst Own72.12% Short Float8.64% Perf Quarter-9.57%
Income35.33M P/S5.67 EPS this Y154.84% Inst Trans6.15% Short Ratio4.62 Perf Half Y-4.49%
Sales84.39M P/B3.59 EPS next Y-55.61% ROA15.30% Short Interest4.80M Perf YTD-5.13%
Book/sh2.37 P/C2.40 EPS next 5Y- ROE34.81% 52W High13.16 -35.41% Perf Year6.38%
Cash/sh3.54 P/FCF- EPS past 3/5Y-2.57% 29.64% ROIC18.07% 52W Low6.19 37.32% Perf 3Y59.18%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-6.24% 12.96% Gross Margin72.58% Volatility3.48% 5.15% Perf 5Y-8.80%
Dividend TTM- EV/Sales4.05 EPS Y/Y TTM132.05% Oper. Margin-34.32% ATR (14)0.43 Perf 10Y-96.19%
Dividend Ex-Date- Quick Ratio8.57 Sales Y/Y TTM240.47% Profit Margin41.86% RSI (14)44.74 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio8.62 EPS Q/Q98.60% SMA20-3.66% Beta0.93 Target Price22.54
Payout- Debt/Eq0.47 Sales Q/Q605.36% SMA50-1.88% Rel Volume0.47 Prev Close8.40
Employees59 LT Debt/Eq0.47 EarningsNov 05 AMC SMA200-9.14% Avg Volume1.04M Price8.50
IPOApr 16, 2015 Option/ShortYes / Yes EPS/Sales Surpr.70.41% -2.12% Trades Volume482,892 Change1.19%
Date Action Analyst Rating Change Price Target Change
Jul-02-25Initiated H.C. Wainwright Buy $26
Jan-08-25Resumed Cantor Fitzgerald Overweight $25
Oct-07-24Initiated Guggenheim Buy $20
Sep-24-24Reiterated Maxim Group Buy $18 → $25
Sep-24-24Initiated JMP Securities Mkt Outperform $17
Apr-02-24Reiterated Maxim Group Buy $12 → $18
Mar-12-24Initiated William Blair Outperform
Mar-17-23Initiated Maxim Group Buy $12
Feb-04-26 07:30AM
Feb-02-26 07:30AM
Jan-26-26 07:30AM
Jan-08-26 07:30AM
Dec-29-25 07:30AM
04:30PM Loading…
Dec-12-25 04:30PM
Dec-02-25 07:30AM
Nov-20-25 04:05PM
Nov-06-25 12:03AM
Nov-05-25 05:50PM
04:48PM
04:05PM
Nov-04-25 08:21AM
Oct-29-25 07:30AM
Oct-27-25 07:30AM
08:55AM Loading…
Oct-16-25 08:55AM
Oct-06-25 05:51PM
01:10PM
Sep-25-25 05:22AM
Sep-18-25 07:30AM
Sep-17-25 02:27PM
Sep-04-25 07:30AM
Aug-28-25 07:30AM
Aug-26-25 07:30AM
Aug-15-25 04:25PM
Aug-13-25 04:09PM
07:30AM
03:11AM
Aug-12-25 05:50PM
04:47PM
04:05PM Loading…
04:05PM
Aug-11-25 09:27AM
09:10AM
Aug-08-25 08:50AM
Aug-06-25 07:30AM
Aug-05-25 10:00AM
Aug-04-25 07:30AM
Jul-31-25 09:55AM
Jul-28-25 06:00AM
Jul-18-25 07:30AM
Jul-17-25 09:11AM
Jul-16-25 12:00PM
09:01AM
07:30AM
Jul-15-25 09:55AM
08:50AM
Jul-11-25 07:30AM
Jul-03-25 08:19AM
May-29-25 04:35PM
May-27-25 01:03PM
May-21-25 07:30AM
May-14-25 10:53AM
03:15AM
May-13-25 05:20PM
04:20PM
04:05PM
May-12-25 09:33AM
May-08-25 08:20AM
May-06-25 07:30AM
May-01-25 04:05PM
Apr-21-25 07:22AM
Apr-17-25 07:30AM
Apr-08-25 12:24AM
Apr-07-25 07:30AM
Apr-03-25 06:38AM
Mar-31-25 04:12PM
Mar-12-25 12:31PM
03:06AM
Mar-11-25 06:15PM
05:22PM
04:05PM
Feb-28-25 07:30AM
06:40AM
Feb-27-25 06:16PM
07:30AM
Feb-26-25 09:46AM
Feb-24-25 04:02PM
Jan-30-25 07:30AM
Jan-29-25 04:05PM
Dec-17-24 07:30AM
Dec-09-24 02:48AM
Dec-06-24 05:00PM
Nov-26-24 07:30AM
Nov-23-24 06:32AM
Nov-21-24 04:51PM
Nov-13-24 02:17AM
Nov-12-24 06:00PM
04:55PM
04:05PM
Nov-11-24 04:36PM
07:15AM
Nov-06-24 07:30AM
Oct-31-24 07:30AM
Oct-29-24 10:01AM
Oct-10-24 07:30AM
Oct-09-24 06:19PM
09:00AM
Sep-25-24 06:22AM
Sep-24-24 07:30AM
Sep-23-24 04:12AM
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McFarlane Neil F.President and CEOFeb 09 '26Sale8.5614,625125,186387,225Feb 10 04:49 PM
Sangiovanni Timothy J.SVP, Finance & Corp ControllerFeb 03 '26Sale9.183,00027,54829,590Feb 04 04:27 PM
Schafer JoshuaCCOFeb 03 '26Sale9.1910,50096,50062,278Feb 04 04:27 PM
Sangiovanni Timothy J.SVP, Finance & Corp ControllerJan 30 '26Sale8.821,75015,44220,924Feb 02 05:19 PM
Thompson RahsaanChief Legal & ComplianceJan 30 '26Sale8.834,08036,01049,919Feb 02 05:19 PM
Quartel Adrian WChief Medical OfficerJan 30 '26Sale8.834,53340,0369,723Feb 02 05:19 PM
Schafer JoshuaCCOJan 30 '26Sale8.833,37529,80037,444Feb 02 05:19 PM
McFarlane Neil F.President and CEOFeb 02 '26Sale9.3891,000853,425364,350Feb 02 05:18 PM
NEIL F MCFARLANEDirectorFeb 02 '26Proposed Sale9.00105,625950,625Feb 02 04:32 PM
TIMOTHY SANGIOVANNIOfficerJan 30 '26Proposed Sale8.864,75042,085Jan 30 04:21 PM
R LaDuane CliftonFormer CFO & TreasurerJan 30 '26Proposed Sale8.8614,000124,040Jan 30 04:20 PM
RAHSAAN THOMPSONOfficerJan 30 '26Proposed Sale8.864,08036,149Jan 30 04:19 PM
JOSHUA SCHAFEROfficerJan 30 '26Proposed Sale8.8613,875122,932Jan 30 04:19 PM
ADRIAN QUARTELOfficerJan 30 '26Proposed Sale8.864,53340,162Jan 30 04:19 PM
Clifton R. LaDuaneFormer CFO & TreasurerDec 31 '25Option Exercise0.00140,6670192,028Jan 07 04:18 PM
McFarlane Neil F.President and CEOOct 10 '25Sale10.8219,500210,908222,016Oct 10 07:17 PM
NEIL F MCFARLANEDirectorOct 10 '25Proposed Sale10.8219,500210,990Oct 10 04:17 PM
FAVORITO TAMARA ADirectorSep 12 '25Buy7.793,17524,7183,894Sep 16 04:15 PM
Shih AlvinDirectorSep 12 '25Buy7.8920,000157,80020,000Sep 15 04:07 PM
Bode John BDirectorAug 19 '25Buy9.165,00045,82545,000Aug 20 04:38 PM
Thompson RahsaanChief Legal & ComplianceJun 26 '25Sale9.2124,000221,00442,666Jun 30 05:02 PM
RAHSAAN THOMPSONOfficerJun 26 '25Proposed Sale9.3324,000223,920Jun 26 04:25 PM
Watton Corey MichaelDirectorMar 28 '25Buy7.843002,3521,800Mar 31 08:05 PM
Bode John BDirectorMar 19 '25Buy7.9610,00079,62440,000Mar 21 04:06 PM
McFarlane Neil F.President and CEOFeb 14 '25Sale8.0530,544245,962191,516Feb 14 05:54 PM